Recombinant protein · Acts on Hyaluronic acid · developed by Bausch And Lomb
ApprovedFDA, May 2004
1Registered trials
What is Hyaluronidase?
Hyaluronidase is an endoglycosidase that hydrolyzes hyaluronic acid in connective tissue, temporarily reducing its viscosity and increasing tissue permeability. It is used as an adjuvant to aid subcutaneous fluid administration, the dispersion and absorption of other injected drugs, and subcutaneous urography. Amphadase was also studied in intradermal injections in subjects with an allergic skin reaction.
Summary written with AI from the sources listed at the end of this page.
Approved as Amphadase, Hylenex Recombinant, Vitrase (May 5, 2004), BLA021640 · FDA label
✅ FDA-approved uses
Subcutaneous fluid administration for achieving hydration (Hylenex Recombinant)
Dispersion and absorption of injected drugs (Hylenex Recombinant)
Subcutaneous urography (Hylenex Recombinant)
Subcutaneous fluid administration for achieving hydration (Amphadase)
Dispersion and absorption of injected drugs (Amphadase)
Subcutaneous urography (Amphadase)
From the indications section of the FDA label (version of Nov 11, 2024). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.